Nielsen, G;
Stone, J;
Buszewicz, M;
Carson, A;
Goldstein, LH;
Holt, K;
Hunter, R;
Marsden, J;
Marston, L;
Noble, H;
et al.
Nielsen, G; Stone, J; Buszewicz, M; Carson, A; Goldstein, LH; Holt, K; Hunter, R; Marsden, J; Marston, L; Noble, H; Reuber, M; Edwards, M; Physio4FMD Collaborative Group
(2019)
Physio4FMD: protocol for a multicentre randomised controlled trial of specialist physiotherapy for functional motor disorder.
BMC Neurology, 19.
p. 242.
ISSN 1471-2377
https://doi.org/10.1186/s12883-019-1461-9
SGUL Authors: Nielsen, Glenn
Abstract
Background
Patients with functional motor disorder (FMD) experience persistent and disabling neurological symptoms such as weakness, tremor, dystonia and disordered gait. Physiotherapy is usually considered an important part of treatment; however, sufficiently-powered controlled studies are lacking. Here we present the protocol of a randomised controlled trial (RCT) that aims to evaluate the clinical and cost effectiveness of a specialist physiotherapy programme for FMD.
Methods/design
The trial is a pragmatic, multicentre, single blind parallel arm randomised controlled trial (RCT). 264 Adults with a clinically definite diagnosis of FMD will be recruited from neurology clinics and randomised to receive either the trial intervention (a specialist physiotherapy protocol) or treatment as usual control (referral to a community physiotherapy service suitable for people with neurological symptoms). Participants will be followed up at 6 and 12 months. The primary outcome is the Physical Function domain of the Short Form 36 questionnaire at 12 months. Secondary domains of measurement will include participant perception of change, mobility, health-related quality of life, health service utilisation, anxiety and depression. Health economic analysis will evaluate the cost impact of trial and control interventions from a health and social care perspective as well as societal perspective.
Discussion
This trial will be the first adequately-powered RCT of physical-based rehabilitation for FMD.
Trial registration
International Standard Randomised Controlled Trials Number ISRCTN56136713. Registered 27 March 2018.
Item Type: |
Article
|
Additional Information: |
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
Keywords: |
1109 Neurosciences, 1702 Cognitive Science, Neurology & Neurosurgery |
SGUL Research Institute / Research Centre: |
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) |
Journal or Publication Title: |
BMC Neurology |
ISSN: |
1471-2377 |
Dates: |
Date | Event |
---|
21 October 2019 | Published | 10 September 2019 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
Projects: |
|
URI: |
https://openaccess.sgul.ac.uk/id/eprint/111324 |
Publisher's version: |
https://doi.org/10.1186/s12883-019-1461-9 |
Statistics
Item downloaded times since 29 Oct 2019.
Actions (login required)
|
Edit Item |